PVLA Stock: Price, Earnings History and SEC Filings
Palvella Therapeutics, Inc. (PVLA) last traded at $146.15, down 3.58% on the latest session and up 6.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.52 against an analyst estimate of $-1.16, a miss of 31.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PVLA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.52 | $-1.16 | -31.03% |
| Mar 2026 | May 7, 2026 | $-1.20 | $-0.90 | -33.33% |
| Dec 2025 | Mar 31, 2026 | $-1.08 | $-0.95 | -13.68% |
| Sep 2025 | Nov 11, 2025 | $-1.03 | $-0.85 | -21.18% |
PVLA beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How PVLA reacts to earnings
Across its last 8 earnings releases, PVLA moved 5.9% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | +7.96% |
| 2026-05-07 | Before open | -12.99% |
| 2026-03-31 | Before open | +12.64% |
| 2026-02-24 | After close | +6.80% |
| 2025-11-10 | After close | -3.04% |
| 2025-08-14 | Before open | +3.27% |
| 2025-05-15 | Before open | -0.41% |
| 2025-03-31 | Before open | -0.39% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PVLA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2023 | $43M | $19M | -$14M | 43.7% | $2.17 |
| 2022 | $26M | -$33M | -$61M | -128.5% | – |
| 2021 | $31M | -$46M | -$9M | -145.6% | $-0.71 |
| 2020 | $29M | -$37M | -$49M | -127.0% | $-0.68 |
| 2019 | $46M | -$25M | -$55M | -55.0% | – |
| 2018 | $29M | -$27M | -$3M | -91.9% | – |
| 2017 | $25M | -$18M | $48M | -69.8% | – |
| 2016 | $6M | -$23M | – | -391.0% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PVLA
- 8-K · Oct 28, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 14, 2026Other events, Financial statements and exhibits
- 8-K · Jun 30, 2026Officer or director change
- 8-K · Jun 16, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 20, 2026Other events, Financial statements and exhibits
- 8-K · May 15, 2026Other events, Financial statements and exhibits
- 8-K · May 13, 2026Other events
- 8-K · May 7, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
PVLA insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PVLA news
- Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026Oct 29, 2026 · finance.yahoo.com
- Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date SetOct 28, 2026 · finance.yahoo.com
- Palvella Gets FDA Priority Review For QTORIN Rapamycin; Decision Expected In February 2027; Stock UpOct 28, 2026 · rttnews.com
- Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline ExpandsOct 25, 2026 · marketbeat.com
- What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?Oct 24, 2026 · finance.yahoo.com
- Ligand to Host Investor Day on December 8, 2026Oct 22, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. (PVLA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in N.V.. Its fiscal year ends in December.